|Company name||Lannett Company, Inc.|
NEW YORK, October 4, 2019 – Bragar Eagel and Squire is investigating certain officers and directors of Lannett Company, Inc. (NASDAQ: LCI) following a class action complaint that was filed against Lannett on November 16, 2016.
According to the complaint, throughout the class period defendants made false and/or misleading statements and/or failed to disclose that: (1) Lannett’s drug pricing relied on unsustainable pricing methodologies; (2) Lannett lacked effective internal controls concerning its drug pricing methodologies; (3) as a result, Linnet’s public statements were materially false and misleading at all relevant times and spurred ongoing investigations by the State of Connecticut Office of the Attorney General and the U.S. Department of Justice. Additionally, media outlets reported that the underlying conduct would likely lead U.S. prosecutors to file criminal charges against Lannett by the end of 2016 for suspected price collusion.
If you purchased or otherwise acquired Lannett Company shares, are a long-term stockholder, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Melissa Fortunato by email at email@example.com, or telephone at (212) 355-4648, or by filling out the contact form below. There is no cost or obligation to you.